company background image
FCM

Friulchem BIT:FCM Stock Report

Last Price

€1.01

Market Cap

€6.1m

7D

-1.9%

1Y

-22.3%

Updated

02 Jul, 2022

Data

Company Financials +
FCM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health4/6
Dividends0/6

FCM Stock Overview

Friulchem S.p.A. engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary fields in Italy.

Friulchem Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Friulchem
Historical stock prices
Current Share Price€1.01
52 Week High€1.38
52 Week Low€0.94
Beta0.81
1 Month Change-1.94%
3 Month Change-12.17%
1 Year Change-22.31%
3 Year Changen/a
5 Year Changen/a
Change since IPO-42.02%

Recent News & Updates

Shareholder Returns

FCMIT PharmaceuticalsIT Market
7D-1.9%-0.01%-2.7%
1Y-22.3%8.9%-17.1%

Return vs Industry: FCM underperformed the Italian Pharmaceuticals industry which returned 8.9% over the past year.

Return vs Market: FCM underperformed the Italian Market which returned -17.1% over the past year.

Price Volatility

Is FCM's price volatile compared to industry and market?
FCM volatility
FCM Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement5.1%
10% most volatile stocks in IT Market7.3%
10% least volatile stocks in IT Market3.3%

Stable Share Price: FCM is less volatile than 75% of Italian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: FCM's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a37Disma Mazzolahttps://www.friulchem.com

Friulchem S.p.A. engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary fields in Italy. It offers generic cosmoceuticals and food supplements; chewable cubes for animals; and cosmetic products for pigmentation disorders. The company is based in Milan, Italy.

Friulchem Fundamentals Summary

How do Friulchem's earnings and revenue compare to its market cap?
FCM fundamental statistics
Market Cap€6.06m
Earnings (TTM)€84.08k
Revenue (TTM)€23.82m

72.1x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FCM income statement (TTM)
Revenue€23.82m
Cost of Revenue€19.07m
Gross Profit€4.75m
Other Expenses€4.67m
Earnings€84.08k

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.014
Gross Margin19.96%
Net Profit Margin0.35%
Debt/Equity Ratio98.6%

How did FCM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is FCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FCM?

Other financial metrics that can be useful for relative valuation.

FCM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA5.5x
PEG Ratio1.4x

Price to Earnings Ratio vs Peers

How does FCM's PE Ratio compare to its peers?

FCM PE Ratio vs Peers
The above table shows the PE ratio for FCM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.2x
SHE Shedir Pharma Group
8.2xn/a€32.0m
PRL Pierrel
18.1x36.8%€46.0m
ABS Arterra Bioscience
12.2xn/a€13.5m
BGD Biogened
10.5xn/azł30.9m
FCM Friulchem
72.1x52.1%€6.1m

Price-To-Earnings vs Peers: FCM is expensive based on its Price-To-Earnings Ratio (72.1x) compared to the peer average (12.2x).


Price to Earnings Ratio vs Industry

How does FCM's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: FCM is expensive based on its Price-To-Earnings Ratio (72.1x) compared to the European Pharmaceuticals industry average (18.4x)


Price to Earnings Ratio vs Fair Ratio

What is FCM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FCM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio72.1x
Fair PE Ratio19.4x

Price-To-Earnings vs Fair Ratio: FCM is expensive based on its Price-To-Earnings Ratio (72.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).


Share Price vs Fair Value

What is the Fair Price of FCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FCM (€1.01) is trading below our estimate of fair value (€3.23)

Significantly Below Fair Value: FCM is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: FCM is poor value based on its PEG Ratio (1.4x)


Discover undervalued companies

Future Growth

How is Friulchem forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


52.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FCM's forecast earnings growth (52.1% per year) is above the savings rate (1.7%).

Earnings vs Market: FCM's earnings (52.1% per year) are forecast to grow faster than the Italian market (10.1% per year).

High Growth Earnings: FCM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FCM's revenue (9.2% per year) is forecast to grow faster than the Italian market (0.3% per year).

High Growth Revenue: FCM's revenue (9.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FCM's Return on Equity is forecast to be low in 3 years time (7.5%).


Discover growth companies

Past Performance

How has Friulchem performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FCM has high quality earnings.

Growing Profit Margin: FCM became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: FCM has become profitable over the past 5 years, growing earnings by -24.4% per year.

Accelerating Growth: FCM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: FCM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.7%).


Return on Equity

High ROE: FCM's Return on Equity (1.3%) is considered low.


Discover strong past performing companies

Financial Health

How is Friulchem's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: FCM's short term assets (€19.8M) exceed its short term liabilities (€11.7M).

Long Term Liabilities: FCM's short term assets (€19.8M) exceed its long term liabilities (€9.6M).


Debt to Equity History and Analysis

Debt Level: FCM's net debt to equity ratio (17.2%) is considered satisfactory.

Reducing Debt: FCM's debt to equity ratio has reduced from 160.3% to 98.6% over the past 5 years.

Debt Coverage: Insufficient data to determine if FCM's debt is well covered by operating cash flow.

Interest Coverage: FCM's interest payments on its debt are not well covered by EBIT (2.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Friulchem current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate FCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FCM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FCM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Disma Mazzola (49 yo)

no data

Tenure

Mr. Disma Giovanni Mazzola is the Chief Executive Officer and Director of Friulchem SpA. He serves as Director at PharmAbbie Inc.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Friulchem S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Friulchem S.p.A.
  • Ticker: FCM
  • Exchange: BIT
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €6.060m
  • Shares outstanding: 6.00m
  • Website: https://www.friulchem.com

Number of Employees


Location

  • Friulchem S.p.A.
  • Via Carlo Ravizza 40
  • Milan
  • Milan
  • 20149
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/02 00:00
End of Day Share Price2022/07/01 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.